<DOC>
	<DOCNO>NCT02180711</DOCNO>
	<brief_summary>To characterize safety profile acalabrutinib alone combination rituximab subject relapse , refractory , treatment naive Follicular Lymphoma ( FL )</brief_summary>
	<brief_title>An Open-label , Phase 1b Study Acalabrutinib Alone Combination With Rituximab Subjects With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Men woman ≥ 18 year age . A confirmed diagnosis FL Grade 1 , 2 , 3a , relapse , refractory ≥ 1 prior therapy FL , subject previously receive systemic anticancer therapy FL. , require treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use contraception study 30 day last dose study drug sexually active able bear beget child . •A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism acalabrutinib , put study outcome undue risk Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , Qtc &gt; 480 msec Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , gastric bypass , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Breast feeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>FL</keyword>
	<keyword>acalabrutinib</keyword>
	<keyword>ACP-196</keyword>
</DOC>